Sector Alpha Week of 2026-07-29
20-quarter listed-company comparison

Pharma - MNC bulk Drugs Stocks in India

Pharma - MNC bulk Drugs: Abbott India Ltd owns the largest revenue base; Sanofi Consumer Healthcare India Ltd has the fastest current growth.

Nifty Pharma - MNC bulk Drugs Index — Constituents & Performance

The Pharma - MNC bulk Drugs companies below are the listed Indian Pharma - MNC bulk Drugs universe this page tracks — the same constituent set people search for as the Nifty Pharma - MNC bulk Drugs index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.

The sector itself · before any single company

How has Pharma - MNC bulk Drugs moved against NIFTY 500?

The line below covers 5.1 years. Over the most recent two of them this sector is 2% ahead of NIFTY 500. Earnings across its companies grew 34% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 6 weeks running.

BREAKING OUT · ahead 6w✓Moving with the index2 of 7 companies ahead of NIFTY 500 by 5% or more over three months

RS ↑6w · 4/7 >200d (+2) · 2/7 lead (+1) · EPS 5/6↑

200300202620252024202320222021 291336 TRAILING 12-MONTH EPS · 100 AT THE START0100173Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 5 reportingSep 2022 · trailing 12-month earnings per share at 109, against 100 at the start · no comparable year yet · 5 reportingDec 2022 · trailing 12-month earnings per share at 121, against 100 at the start · no comparable year yet · 5 reportingMar 2023 · trailing 12-month earnings per share at 125, against 100 at the start · no comparable year yet · 5 reportingJun 2023 · trailing 12-month earnings per share at 128, against 100 at the start · up 27.9% on a year ago · 5 reportingSep 2023 · trailing 12-month earnings per share at 120, against 100 at the start · up 15.3% on a year ago · 5 reportingDec 2023 · trailing 12-month earnings per share at 118, against 100 at the start · down 2.6% on a year ago · 5 reportingMar 2024 · trailing 12-month earnings per share at 118, against 100 at the start · down 3.4% on a year ago · 6 reportingJun 2024 · trailing 12-month earnings per share at 119, against 100 at the start · down 11.1% on a year ago · 6 reportingSep 2024 · trailing 12-month earnings per share at 114, against 100 at the start · up 4.2% on a year ago · 6 reportingDec 2024 · trailing 12-month earnings per share at 129, against 100 at the start · up 16.5% on a year ago · 6 reportingMar 2025 · trailing 12-month earnings per share at 146, against 100 at the start · up 17.7% on a year ago · 6 reportingJun 2025 · trailing 12-month earnings per share at 168, against 100 at the start · up 48.5% on a year ago · 6 reportingSep 2025 · trailing 12-month earnings per share at 173, against 100 at the start · up 40.9% on a year ago · 6 reportingDec 2025 · trailing 12-month earnings per share at 171, against 100 at the start · up 24.1% on a year ago · 6 reportingMar 2026 · trailing 12-month earnings per share at 166, against 100 at the start · up 20.9% on a year ago · 6 reportingNot reported yet — earnings trail price by a quarter or two166 · Mar 26No earnings on file this far back — the price series reaches further than the filings doNO EARNINGS ON FILE
200300202620252024202320222021 291336 TRAILING 12-MONTH EPS · 100 AT THE START0100173Mar 23Mar 24Mar 25Mar 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 5 reportingSep 2022 · trailing 12-month earnings per share at 109, against 100 at the start · no comparable year yet · 5 reportingDec 2022 · trailing 12-month earnings per share at 121, against 100 at the start · no comparable year yet · 5 reportingMar 2023 · trailing 12-month earnings per share at 125, against 100 at the start · no comparable year yet · 5 reportingJun 2023 · trailing 12-month earnings per share at 128, against 100 at the start · up 27.9% on a year ago · 5 reportingSep 2023 · trailing 12-month earnings per share at 120, against 100 at the start · up 15.3% on a year ago · 5 reportingDec 2023 · trailing 12-month earnings per share at 118, against 100 at the start · down 2.6% on a year ago · 5 reportingMar 2024 · trailing 12-month earnings per share at 118, against 100 at the start · down 3.4% on a year ago · 6 reportingJun 2024 · trailing 12-month earnings per share at 119, against 100 at the start · down 11.1% on a year ago · 6 reportingSep 2024 · trailing 12-month earnings per share at 114, against 100 at the start · up 4.2% on a year ago · 6 reportingDec 2024 · trailing 12-month earnings per share at 129, against 100 at the start · up 16.5% on a year ago · 6 reportingMar 2025 · trailing 12-month earnings per share at 146, against 100 at the start · up 17.7% on a year ago · 6 reportingJun 2025 · trailing 12-month earnings per share at 168, against 100 at the start · up 48.5% on a year ago · 6 reportingSep 2025 · trailing 12-month earnings per share at 173, against 100 at the start · up 40.9% on a year ago · 6 reportingDec 2025 · trailing 12-month earnings per share at 171, against 100 at the start · up 24.1% on a year ago · 6 reportingMar 2026 · trailing 12-month earnings per share at 166, against 100 at the start · up 20.9% on a year ago · 6 reportingNot reported yet — earnings trail price by a quarter or two166No earnings on file this far back — the price series reaches further than the filings do
Pharma - MNC bulk Drugs, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling
Strength anatomy NarrowHow much of the sector is participating, how recently, and whether the movers score well.
Together2 of 7 stocks moving
Fresh1 crossed in the last 4 weeks
Backed by scoresmovers score +10 vs the sector average
Down the cap ladder — bar is now, tick is four weeks ago
Large 1/2+1
Mid 0/20
Small 1/30

Participation is not spreading downward this month; the larger companies are still carrying most of it.

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 7 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

Sector relative strength · before individual stocks

Is Pharma - MNC bulk Drugs outperforming NIFTY 500?

The 52-week comparison of Pharma - MNC bulk Drugs against NIFTY 500 is not available from the current market series. 2 of 8 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Novartis India Ltd is the strongest against the sector itself at +49.4%. Readings are as of 2026-07-19.

—Sector vs NIFTY 500 · 13 weeks
—Sector vs NIFTY 500 · 52 weeks
2/8Stocks leading NIFTY 500
2/8Stocks leading sector

Sector metric: 44.5 as of 2026-07-19 · NARROWING · rising.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

The 52-week sector comparison is unavailable. 2 of 8 covered companies currently have positive Mansfield relative strength versus NIFTY 500. Abbott India Ltd leads with revenue of ₹6,929 crore, based on 8 of 8 comparable companies through Mar 2026. Sanofi Consumer Healthcare India Ltd has the fastest current revenue growth at 38.3%, across 7 of 8 comparable companies.

Is the Pharma - MNC bulk Drugs sector outperforming NIFTY 500?

The 52-week sector comparison is unavailable. 2 of 8 covered companies currently have positive Mansfield relative strength versus NIFTY 500.

Which Pharma - MNC bulk Drugs company is largest by revenue?

Abbott India Ltd leads with revenue of ₹6,929 crore, based on 8 of 8 comparable companies through Mar 2026.

Which Pharma - MNC bulk Drugs company is growing fastest?

Sanofi Consumer Healthcare India Ltd has the fastest current revenue growth at 38.3%, across 7 of 8 comparable companies.

Which Pharma - MNC bulk Drugs company has the strongest 4-Factor Sector Score?

Procter & Gamble Health Ltd ranks first at 75.1/100 with 89.6% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Pharma - MNC bulk Drugs company has the least gross debt?

Novartis India Ltd has the lowest comparable gross debt at ₹3 crore. Abbott India Ltd has the highest at ₹172 crore.

Which Pharma - MNC bulk Drugs company has the lowest comparable PEG?

Procter & Gamble Health Ltd has the lowest comparable Guarded PEG at 0.5, among 6 of 8 companies that pass the metric’s comparability rules.

How much history does this Pharma - MNC bulk Drugs comparison include?

The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Companies
8
complete canonical membership
Combined market value
₹1.8 L Cr
Abbott India Ltd
Revenue growing
7/7
positive TTM year-on-year growth
Beating NIFTY 500
2/8
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Procter & Gamble Health Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 89.6% evidence confidence.
Pfizer Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Novartis India Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.

1. Procter & Gamble Health Ltd · PGHL

75.1/100 · Favorable setup · 90% evidence

Exact sum: 28.7 + 20.1 + 14.6 + 11.7 = 75.1

Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

28.7/35Growth & earnings

Revenue 15.6% · PAT 30.7% · OPM change 11 pp

88% evidence

20.1/25Capital efficiency

ROCE 83.5% · debt/equity 0.02×

100% evidence

14.6/20Valuation

P/E 34.1× · PEG 0.5

100% evidence

11.7/20Relative strength

RS sector -2.5% · RS bench 17% · 1Y 16%

70% evidence

2. Sanofi Consumer Healthcare India Ltd · SANOFICONR

57.9/100 · Mixed-positive evidence · 65% evidence

Exact sum: 25.2 + 18.6 + 9.4 + 4.7 = 57.9

Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.2% and the one-year return is -10.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.

25.2/35Growth & earnings

Revenue 38.3% · PAT 53.6% · OPM change 2 pp

62% evidence

18.6/25Capital efficiency

ROCE 89.9% · debt/equity 0.07×

80% evidence

9.4/20Valuation

P/E 42.6× · PEG —

15% evidence

4.7/20Relative strength

RS sector -7.2% · RS bench -3% · 1Y -10.3%

100% evidence

3. Novartis India Ltd · NOVARTIND

52.0/100 · Mixed-positive evidence · 100% evidence

Exact sum: 14.2 + 11.2 + 6.6 + 20 = 52

Decision use: Price leads the evidence: RS versus the benchmark is 55.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

14.2/35Growth & earnings

Revenue 5.4% · PAT -4.9% · OPM change 3 pp

100% evidence

11.2/25Capital efficiency

ROCE 16.2% · debt/equity 0×

100% evidence

6.6/20Valuation

P/E 41.4× · PEG 1.96

100% evidence

20.0/20Relative strength

RS sector 49.4% · RS bench 55.8% · 1Y 47.3%

100% evidence

4. Abbott India Ltd · ABBOTINDIA

49.5/100 · Mixed-negative evidence · 90% evidence

Exact sum: 15.4 + 14.6 + 8.2 + 11.3 = 49.5

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

15.4/35Growth & earnings

Revenue 8.1% · PAT 9.7% · OPM change 1 pp

88% evidence

14.6/25Capital efficiency

ROCE 44.8% · debt/equity 0.04×

100% evidence

8.2/20Valuation

P/E 38.5× · PEG 2.56

100% evidence

11.3/20Relative strength

RS sector -0.7% · RS bench -2.2% · 1Y -17.8%

70% evidence

5. Pfizer Ltd · PFIZER

49.0/100 · Mixed-negative evidence · 96% evidence

Exact sum: 15.6 + 14.3 + 17.3 + 1.8 = 49

Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.

15.6/35Growth & earnings

Revenue 10.4% · PAT -5.9% · OPM change 0 pp

88% evidence

14.3/25Capital efficiency

ROCE 24.1% · debt/equity 0.02×

100% evidence

17.3/20Valuation

P/E 27.9× · PEG 1.19

100% evidence

1.8/20Relative strength

RS sector -12.3% · RS bench -8.2% · 1Y -14.1%

100% evidence

6. Glaxosmithkline Pharmaceuticals Ltd · GLAXO

41.0/100 · Mixed-negative evidence · 96% evidence

Exact sum: 12.3 + 20.1 + 5.3 + 3.3 = 41

Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.

12.3/35Growth & earnings

Revenue 1.9% · PAT 11.8% · OPM change 1 pp

88% evidence

20.1/25Capital efficiency

ROCE 61.4% · debt/equity 0.01×

100% evidence

5.3/20Valuation

P/E 44.3× · PEG 6.68

100% evidence

3.3/20Relative strength

RS sector -8.1% · RS bench -3.9% · 1Y -21.8%

100% evidence

7. Astrazeneca Pharma India Ltd · ASTRAZEN

39.8/100 · Mixed-negative evidence · 83% evidence

Exact sum: 16.3 + 8.4 + 4.3 + 10.8 = 39.8

Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

16.3/35Growth & earnings

Revenue 32.6% · PAT 63.5% · OPM change -7 pp

88% evidence

8.4/25Capital efficiency

ROCE 29.3% · debt/equity 0.13×

100% evidence

4.3/20Valuation

P/E 105× · PEG 3.95

65% evidence

10.8/20Relative strength

RS sector 2.3% · RS bench -8.5% · 1Y -12%

70% evidence

8. Sanofi India Ltd · SANOFI

50.1/100 · Thin evidence · provisional · 41% evidence

Exact sum: 17.9 + 15.3 + 13.9 + 3 = 50.1

Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

17.9/35Growth & earnings

Revenue — · PAT — · OPM change 2 pp

5% evidence

15.3/25Capital efficiency

ROCE 49.2% · debt/equity 0.02×

60% evidence

13.9/20Valuation

P/E 17.6× · PEG —

50% evidence

3.0/20Relative strength

RS sector -26.7% · RS bench -17.9% · 1Y -42.6%

70% evidence

01 · compare level, then change

Revenue Scale & Growth Durability

Abbott India Ltd has the highest Revenue among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹6,929 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹3,821 crore. Sanofi Consumer Healthcare India Ltd has the highest Revenue growth at 38.3%, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.

What the numbers say: Abbott India Ltd is the scale leader at ₹6,929 crore, 81.3% ahead of Glaxosmithkline Pharmaceuticals Ltd. Sanofi Consumer Healthcare India Ltd's growth is 38.3% from a ₹935 crore base, with 11 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderAbbott India Ltd · ₹6,929 crore
Gap81.3% versus #2 · Glaxosmithkline Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage8/8 companies · 133 observations

Investor read: Abbott India Ltd is the scale benchmark; Sanofi Consumer Healthcare India Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Abbott India Ltd's growth falls below Sanofi Consumer Healthcare India Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Abbott India Ltd ABBOTINDIA₹6.9K Cr
2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹3.8K Cr
3Pfizer Ltd PFIZER₹2.5K Cr
4Astrazeneca Pharma India Ltd ASTRAZEN₹2.3K Cr
5Sanofi India Ltd SANOFI · older report₹2.0K Cr
Revenue growthfastest growers
1Sanofi Consumer Healthcare India Ltd SANOFICONR38%
2Astrazeneca Pharma India Ltd ASTRAZEN33%
3Procter & Gamble Health Ltd PGHL16%
4Pfizer Ltd PFIZER10%
5Abbott India Ltd ABBOTINDIA8.1%
Revenue · company comparison
8/8 level · 7/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Abbott India Ltd ABBOTINDIA₹1.7K Cr6.5%Mar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹995 Cr2.2%Mar 2026
Pfizer Ltd PFIZER₹629 Cr6.3%Mar 2026
Astrazeneca Pharma India Ltd ASTRAZEN₹579 Cr21%Mar 2026
Sanofi India Ltd SANOFI₹515 Cr9.8%Dec 2024
Procter & Gamble Health Ltd PGHL₹370 Cr19%Mar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR₹229 Cr32%Mar 2026
Novartis India Ltd NOVARTIND₹104 Cr18%Jun 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹1.2K Cr
₹1.2K Cr
₹1.2K Cr
₹1.3K Cr
₹1.4K Cr
₹1.3K Cr
₹1.3K Cr
₹1.5K Cr
₹1.5K Cr
₹1.4K Cr
₹1.4K Cr
₹1.6K Cr
₹1.6K Cr
₹1.6K Cr
₹1.6K Cr
₹1.7K Cr
₹1.8K Cr
₹1.7K Cr
₹1.7K Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

₹198 Cr
₹201 Cr
₹232 Cr
₹232 Cr
₹236 Cr
₹250 Cr
₹285 Cr
₹295 Cr
₹311 Cr
₹306 Cr
₹383 Cr
₹388 Cr
₹408 Cr
₹440 Cr
₹480 Cr
₹526 Cr
₹559 Cr
₹612 Cr
₹579 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹1.0K Cr
₹816 Cr
₹810 Cr
₹745 Cr
₹917 Cr
₹802 Cr
₹787 Cr
₹762 Cr
₹957 Cr
₹805 Cr
₹930 Cr
₹815 Cr
₹1.0K Cr
₹949 Cr
₹974 Cr
₹805 Cr
₹980 Cr
₹1.0K Cr
₹995 Cr
—

Novartis India Ltd · NOVARTIND

₹104 Cr
₹99 Cr
₹98 Cr
₹121 Cr
₹102 Cr
₹80 Cr
₹76 Cr
₹91 Cr
₹79 Cr
₹85 Cr
₹81 Cr
₹92 Cr
₹87 Cr
₹93 Cr
₹84 Cr
₹88 Cr
₹90 Cr
₹86 Cr
₹91 Cr
₹104 Cr

Pfizer Ltd · PFIZER

₹636 Cr
₹676 Cr
₹550 Cr
₹593 Cr
₹637 Cr
₹622 Cr
₹573 Cr
₹531 Cr
₹575 Cr
₹540 Cr
₹547 Cr
₹563 Cr
₹589 Cr
₹538 Cr
₹592 Cr
₹603 Cr
₹642 Cr
₹645 Cr
₹629 Cr
—

Procter & Gamble Health Ltd · PGHL

₹273 Cr
₹278 Cr
₹268 Cr
₹296 Cr
₹298 Cr
₹310 Cr
₹321 Cr
₹301 Cr
₹305 Cr
₹310 Cr
₹252 Cr
₹284 Cr
₹313 Cr
₹310 Cr
₹311 Cr
₹339 Cr
₹325 Cr
₹374 Cr
₹370 Cr
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
₹210 Cr
₹225 Cr
₹222 Cr
₹172 Cr
₹160 Cr
₹171 Cr
₹173 Cr
₹221 Cr
₹234 Cr
₹251 Cr
₹229 Cr
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
₹515 Cr
₹491 Cr
₹469 Cr
₹511 Cr
₹464 Cr
₹524 Cr
₹515 Cr
—
—
—
—
—
—

Revenue growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
7.1%
13%
8.0%
7.5%
13%
8.3%
8.7%
7.2%
5.3%
9.3%
12%
12%
12%
7.6%
6.8%
6.5%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
33%
19%
24%
23%
27%
32%
22%
34%
32%
31%
44%
25%
36%
37%
39%
21%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
-5.7%
-9.2%
-1.7%
-2.8%
2.3%
4.4%
0.4%
18%
7.0%
5.6%
18%
4.7%
-1.2%
-3.1%
9.7%
2.2%
—

Novartis India Ltd · NOVARTIND

—
—
—
23%
-1.9%
-19%
-22%
-25%
-23%
6.3%
6.6%
1.1%
10%
9.4%
3.7%
-4.4%
3.5%
-7.5%
8.3%
18%

Pfizer Ltd · PFIZER

—
—
—
-21%
0.2%
-8.0%
4.2%
-10%
-9.7%
-13%
-4.5%
6.0%
2.4%
-0.4%
8.2%
7.1%
9.0%
20%
6.3%
—

Procter & Gamble Health Ltd · PGHL

—
—
—
3.9%
9.2%
12%
20%
1.7%
2.4%
0.0%
-22%
-5.7%
2.6%
0.0%
23%
19%
3.8%
21%
19%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
-24%
-24%
-22%
28%
46%
47%
32%
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
—
-9.9%
6.7%
9.8%
—
—
—
—
—
—
02 · compare level, then change

Operating Economics & Margin Trend

Sanofi Consumer Healthcare India Ltd has the highest OPM among the 8 Pharma - MNC bulk Drugs companies compared here, at 39%. Pfizer Ltd is next at 38%. Procter & Gamble Health Ltd has the highest Margin change at +11 percentage points, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads opm at 39%; Procter & Gamble Health Ltd leads margin change at +11 percentage points.

LeaderSanofi Consumer Healthcare India Ltd · 39%
Gap2.6% versus #2 · Pfizer Ltd
Persistence1/7 recent comparable periods
Coverage8/8 companies · 140 observations

Investor read: Sanofi Consumer Healthcare India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Sanofi Consumer Healthcare India Ltd SANOFICONR39%
2Pfizer Ltd PFIZER38%
3Procter & Gamble Health Ltd PGHL37%
4Glaxosmithkline Pharmaceuticals Ltd GLAXO35%
5Novartis India Ltd NOVARTIND34%
Margin changefastest expanders
1Procter & Gamble Health Ltd PGHL+11.0 pp
2Novartis India Ltd NOVARTIND+3.0 pp
3Sanofi India Ltd SANOFI · older report+2.0 pp
4Sanofi Consumer Healthcare India Ltd SANOFICONR+2.0 pp
5Abbott India Ltd ABBOTINDIA+1.0 pp
Operating margin · company comparison
8/8 level · 8/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyOPMMargin changeReported
Sanofi Consumer Healthcare India Ltd SANOFICONR39%+2.0 ppMar 2026
Pfizer Ltd PFIZER38%0.0 ppMar 2026
Procter & Gamble Health Ltd PGHL37%+11.0 ppMar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO35%+1.0 ppMar 2026
Novartis India Ltd NOVARTIND34%+3.0 ppJun 2026
Abbott India Ltd ABBOTINDIA28%+1.0 ppMar 2026
Sanofi India Ltd SANOFI23%+2.0 ppDec 2024
Astrazeneca Pharma India Ltd ASTRAZEN11%−7.0 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Abbott India Ltd · ABBOTINDIA

21%
22%
23%
21%
25%
24%
21%
24%
25%
27%
23%
25%
27%
27%
27%
26%
29%
27%
28%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

9.1%
7.3%
16%
12%
17%
15%
21%
23%
17%
5.0%
13%
10%
13%
17%
18%
15%
13%
7.0%
11%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

27%
24%
22%
20%
28%
29%
22%
19%
30%
27%
28%
28%
32%
31%
34%
31%
34%
36%
35%
—

Novartis India Ltd · NOVARTIND

6.8%
6.6%
5.7%
26%
16%
10%
12%
19%
21%
23%
14%
26%
21%
28%
29%
31%
26%
26%
23%
34%

Pfizer Ltd · PFIZER

30%
29%
30%
32%
36%
33%
32%
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
—

Procter & Gamble Health Ltd · PGHL

29%
22%
26%
20%
31%
35%
25%
15%
29%
33%
27%
17%
36%
40%
26%
27%
37%
30%
37%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
45%
40%
37%
37%
39%
36%
37%
32%
36%
36%
39%
—

Sanofi India Ltd · SANOFI

26%
18%
28%
23%
26%
25%
31%
24%
23%
21%
27%
25%
23%
23%
—
—
—
—
—
—

Margin change · reported quarter history

Abbott India Ltd · ABBOTINDIA

−1.6 pp
−0.1 pp
+4.6 pp
−1.1 pp
+3.6 pp
+2.0 pp
−2.4 pp
+3.3 pp
+0.1 pp
+3.0 pp
+2.0 pp
+1.0 pp
+2.0 pp
0.0 pp
+4.0 pp
+1.0 pp
+2.0 pp
0.0 pp
+1.0 pp
—

Astrazeneca Pharma India Ltd · ASTRAZEN

−8.0 pp
−8.0 pp
−2.9 pp
+3.1 pp
+8.2 pp
+7.7 pp
+4.6 pp
+11.0 pp
−0.3 pp
−10.0 pp
−8.0 pp
−13.0 pp
−4.0 pp
+12.0 pp
+5.0 pp
+5.0 pp
0.0 pp
−10.0 pp
−7.0 pp
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

+4.1 pp
+1.4 pp
+0.6 pp
+1.5 pp
+0.6 pp
+4.8 pp
+0.4 pp
−1.0 pp
+2.0 pp
−2.0 pp
+6.0 pp
+9.0 pp
+2.0 pp
+4.0 pp
+6.0 pp
+3.0 pp
+2.0 pp
+5.0 pp
+1.0 pp
—

Novartis India Ltd · NOVARTIND

−3.9 pp
+9.7 pp
−9.7 pp
+18.3 pp
+9.3 pp
+3.4 pp
+6.3 pp
−7.3 pp
+4.9 pp
+13.0 pp
+2.0 pp
+7.0 pp
0.0 pp
+5.0 pp
+15.0 pp
+5.0 pp
+5.0 pp
−2.0 pp
−6.0 pp
+3.0 pp

Pfizer Ltd · PFIZER

−4.4 pp
−4.3 pp
+6.6 pp
−5.8 pp
+6.6 pp
+4.1 pp
+1.9 pp
−11.4 pp
−4.4 pp
−5.0 pp
+3.0 pp
+11.0 pp
0.0 pp
−1.0 pp
+3.0 pp
+3.0 pp
+4.0 pp
+8.0 pp
0.0 pp
—

Procter & Gamble Health Ltd · PGHL

−1.0 pp
−14.7 pp
+11.7 pp
+3.0 pp
+1.9 pp
+12.8 pp
−0.7 pp
−5.0 pp
−1.5 pp
−2.0 pp
+2.0 pp
+2.0 pp
+7.0 pp
+7.0 pp
−1.0 pp
+10.0 pp
+1.0 pp
−10.0 pp
+11.0 pp
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
−6.0 pp
−4.0 pp
0.0 pp
−5.0 pp
−3.0 pp
0.0 pp
+2.0 pp
—

Sanofi India Ltd · SANOFI

−1.6 pp
−4.7 pp
+1.4 pp
−8.3 pp
−0.1 pp
+6.4 pp
+3.7 pp
+1.0 pp
−3.3 pp
−3.8 pp
−4.2 pp
+1.0 pp
0.0 pp
+2.0 pp
—
—
—
—
—
—
03 · compare level, then change

Profit Scale & Acceleration

Abbott India Ltd has the highest Net profit among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹1,552 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹1,036 crore. Astrazeneca Pharma India Ltd has the highest Profit growth at 63.5%, so level and change sit with different companies.

What the numbers say: Abbott India Ltd leads with ₹1,552 crore of TTM profit, 49.8% above Glaxosmithkline Pharmaceuticals Ltd. Astrazeneca Pharma India Ltd shows 63.5% growth from a ₹188 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderAbbott India Ltd · ₹1,552 crore
Gap49.8% versus #2 · Glaxosmithkline Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage8/8 companies · 133 observations

Investor read: Abbott India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Abbott India Ltd ABBOTINDIA₹1.6K Cr
2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹1.0K Cr
3Pfizer Ltd PFIZER₹723 Cr
4Sanofi India Ltd SANOFI · older report₹413 Cr
5Procter & Gamble Health Ltd PGHL₹328 Cr
Profit growthfastest growers
1Astrazeneca Pharma India Ltd ASTRAZEN64%
2Sanofi Consumer Healthcare India Ltd SANOFICONR54%
3Procter & Gamble Health Ltd PGHL31%
4Glaxosmithkline Pharmaceuticals Ltd GLAXO12%
5Abbott India Ltd ABBOTINDIA9.7%
Net profit · company comparison
8/8 level · 7/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyNet profitProfit growthReported
Abbott India Ltd ABBOTINDIA₹395 Cr7.6%Mar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹278 Cr5.7%Mar 2026
Pfizer Ltd PFIZER₹200 Cr-40%Mar 2026
Procter & Gamble Health Ltd PGHL₹95 Cr56%Mar 2026
Sanofi India Ltd SANOFI₹91 Cr-34%Dec 2024
Sanofi Consumer Healthcare India Ltd SANOFICONR₹68 Cr36%Mar 2026
Astrazeneca Pharma India Ltd ASTRAZEN₹45 Cr-22%Mar 2026
Novartis India Ltd NOVARTIND₹32 Cr14%Jun 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹192 Cr
₹199 Cr
₹211 Cr
₹206 Cr
₹266 Cr
₹247 Cr
₹231 Cr
₹290 Cr
₹313 Cr
₹311 Cr
₹287 Cr
₹328 Cr
₹359 Cr
₹361 Cr
₹367 Cr
₹366 Cr
₹415 Cr
₹376 Cr
₹395 Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

₹12 Cr
₹11 Cr
₹28 Cr
₹20 Cr
₹33 Cr
₹29 Cr
₹17 Cr
₹54 Cr
₹52 Cr
₹16 Cr
₹39 Cr
₹-12 Cr
₹38 Cr
₹31 Cr
₹58 Cr
₹56 Cr
₹54 Cr
₹33 Cr
₹45 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹204 Cr
₹150 Cr
₹1.2K Cr
₹119 Cr
₹193 Cr
₹165 Cr
₹133 Cr
₹132 Cr
₹218 Cr
₹46 Cr
₹194 Cr
₹182 Cr
₹252 Cr
₹230 Cr
₹263 Cr
₹205 Cr
₹257 Cr
₹296 Cr
₹278 Cr
—

Novartis India Ltd · NOVARTIND

₹7 Cr
₹6 Cr
₹-23 Cr
₹52 Cr
₹18 Cr
₹8 Cr
₹25 Cr
₹20 Cr
₹24 Cr
₹27 Cr
₹15 Cr
₹26 Cr
₹20 Cr
₹25 Cr
₹29 Cr
₹28 Cr
₹24 Cr
₹16 Cr
₹25 Cr
₹32 Cr

Pfizer Ltd · PFIZER

₹143 Cr
₹144 Cr
₹126 Cr
₹33 Cr
₹311 Cr
₹151 Cr
₹130 Cr
₹94 Cr
₹149 Cr
₹130 Cr
₹179 Cr
₹151 Cr
₹158 Cr
₹128 Cr
₹331 Cr
₹192 Cr
₹189 Cr
₹142 Cr
₹200 Cr
—

Procter & Gamble Health Ltd · PGHL

₹55 Cr
₹45 Cr
₹51 Cr
₹41 Cr
₹64 Cr
₹77 Cr
₹59 Cr
₹30 Cr
₹66 Cr
₹72 Cr
₹47 Cr
₹17 Cr
₹82 Cr
₹91 Cr
₹61 Cr
₹66 Cr
₹89 Cr
₹78 Cr
₹95 Cr
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
₹71 Cr
₹68 Cr
₹63 Cr
₹29 Cr
₹45 Cr
₹44 Cr
₹50 Cr
₹61 Cr
₹63 Cr
₹66 Cr
₹68 Cr
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
₹123 Cr
₹152 Cr
₹138 Cr
₹137 Cr
₹103 Cr
₹82 Cr
₹91 Cr
—
—
—
—
—
—

Profit growth · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
5.1%
39%
24%
9.5%
41%
18%
26%
24%
13%
15%
16%
28%
12%
16%
4.2%
7.6%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
100%
175%
164%
-39%
170%
58%
-45%
129%
-122%
-27%
94%
49%
—
42%
6.5%
-22%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
-1.7%
-5.4%
10%
-89%
11%
13%
-72%
46%
38%
16%
400%
36%
13%
2.0%
29%
5.7%
—

Novartis India Ltd · NOVARTIND

—
—
—
767%
157%
33%
—
-62%
33%
238%
-40%
30%
-17%
-7.4%
93%
7.7%
20%
-36%
-14%
14%

Pfizer Ltd · PFIZER

—
—
—
-84%
117%
4.9%
3.2%
185%
-52%
-14%
38%
61%
6.0%
-1.5%
85%
27%
20%
11%
-40%
—

Procter & Gamble Health Ltd · PGHL

—
—
—
21%
16%
71%
16%
-27%
3.1%
-6.5%
-20%
-43%
24%
26%
30%
288%
8.5%
-14%
56%
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
-37%
-35%
-21%
110%
40%
50%
36%
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
—
-16%
-46%
-34%
—
—
—
—
—
—
04 · not available

Capacity Spending & Returns On It

No company in this Pharma - MNC bulk Drugs comparison reports capital expenditure on a comparable basis, so there is nothing to rank here — 0 of 8 companies have a usable current reading. The section is shown rather than removed so an unavailable metric is not mistaken for one that was quietly left out.

CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.

Withheld from this comparison: Sanofi Consumer Healthcare India Ltd (SANOFICONR) — its two data sources disagree by up to 132% on reported income across 11 comparable periods, so its derived ratios are withheld; Sanofi India Ltd (SANOFI) — its two data sources disagree by up to 45% on reported income across 6 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

05 · compare level, then change

Debt Load & Balance-Sheet Headroom

Novartis India Ltd has the lowest Gross debt among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹3 crore. Procter & Gamble Health Ltd is next at ₹9 crore. Pfizer Ltd has the lowest Net debt at ₹3,018 crore net cash, so level and change sit with different companies.

What the numbers say: Pfizer Ltd has the clearest covered balance-sheet capacity with ₹3,018 crore net cash and gross debt of ₹70 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.

LeaderNovartis India Ltd · ₹3 crore
Gap66.7% versus #2 · Procter & Gamble Health Ltd
Persistence8/8 recent comparable periods
Coverage8/8 companies · 115 observations

Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.

This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.

Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1Novartis India Ltd NOVARTIND₹3 Cr
2Procter & Gamble Health Ltd PGHL₹9 Cr
3Sanofi India Ltd SANOFI · older report₹19 Cr
4Sanofi Consumer Healthcare India Ltd SANOFICONR₹25 Cr
5Glaxosmithkline Pharmaceuticals Ltd GLAXO₹33 Cr
Net debtlowest net debt
1Pfizer Ltd PFIZER₹-3.0K Cr
2Glaxosmithkline Pharmaceuticals Ltd GLAXO₹-2.7K Cr
3Abbott India Ltd ABBOTINDIA₹-2.2K Cr
4Novartis India Ltd NOVARTIND₹-665 Cr
5Astrazeneca Pharma India Ltd ASTRAZEN₹-338 Cr
Debt and balance-sheet capacity · company comparison
8/8 level · 6/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyGross debtNet debtReported
Abbott India Ltd ABBOTINDIA₹172 Cr₹-2.2K CrMar 2026
Astrazeneca Pharma India Ltd ASTRAZEN₹111 Cr₹-338 CrMar 2026
Pfizer Ltd PFIZER₹70 Cr₹-3.0K CrMar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹33 Cr₹-2.7K CrMar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR₹25 Cr—Mar 2026
Sanofi India Ltd SANOFI₹19 Cr—Dec 2024
Procter & Gamble Health Ltd PGHL₹9 Cr₹-176 CrMar 2026
Novartis India Ltd NOVARTIND₹3 Cr₹-665 CrJun 2026
Full 20-quarter history · every available company

Gross debt · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹161 Cr
₹161 Cr
₹152 Cr
₹152 Cr
₹129 Cr
₹129 Cr
₹113 Cr
₹113 Cr
₹92 Cr
₹92 Cr
₹83 Cr
₹83 Cr
₹61 Cr
₹61 Cr
₹197 Cr
₹197 Cr
₹182 Cr
₹182 Cr
₹172 Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
₹9 Cr
₹9 Cr
₹7 Cr
₹7 Cr
₹7 Cr
₹7 Cr
₹5 Cr
₹5 Cr
₹5 Cr
₹5 Cr
₹17 Cr
₹17 Cr
₹36 Cr
₹36 Cr
₹35 Cr
₹35 Cr
₹111 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹28 Cr
₹28 Cr
₹20 Cr
₹20 Cr
₹23 Cr
₹23 Cr
₹16 Cr
₹16 Cr
₹21 Cr
₹21 Cr
₹19 Cr
₹19 Cr
₹15 Cr
₹15 Cr
₹10 Cr
₹10 Cr
₹36 Cr
₹36 Cr
₹33 Cr
—

Novartis India Ltd · NOVARTIND

₹59 Cr
₹59 Cr
₹24 Cr
₹24 Cr
₹22 Cr
₹22 Cr
₹22 Cr
₹22 Cr
₹8 Cr
₹8 Cr
₹7 Cr
₹7 Cr
₹6 Cr
₹6 Cr
₹5 Cr
₹5 Cr
₹4 Cr
₹4 Cr
₹3 Cr
—

Pfizer Ltd · PFIZER

₹101 Cr
₹101 Cr
₹39 Cr
₹167 Cr
₹151 Cr
₹151 Cr
₹41 Cr
₹134 Cr
₹116 Cr
₹116 Cr
₹40 Cr
₹95 Cr
₹75 Cr
₹75 Cr
₹108 Cr
₹108 Cr
₹43 Cr
₹90 Cr
₹70 Cr
—

Procter & Gamble Health Ltd · PGHL

₹8 Cr
₹0 Cr
₹0 Cr
₹3 Cr
₹3 Cr
₹13 Cr
₹13 Cr
₹12 Cr
₹12 Cr
₹11 Cr
—
₹10 Cr
—
—
₹8 Cr
₹8 Cr
₹6 Cr
₹6 Cr
₹9 Cr
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
₹0 Cr
—
—
—
₹20 Cr
—
₹28 Cr
—
₹25 Cr
—
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
₹19 Cr
—
—
—
₹19 Cr
—
—
—
—
—
—

Net debt · reported quarter history

Abbott India Ltd · ABBOTINDIA

₹-2.1K Cr
₹-2.1K Cr
₹-2.6K Cr
₹-2.6K Cr
₹-1.7K Cr
₹-1.7K Cr
₹-1.8K Cr
₹-1.8K Cr
₹-1.9K Cr
₹-1.9K Cr
₹-2.0K Cr
₹-2.0K Cr
₹-1.0K Cr
₹-1.0K Cr
₹-2.9K Cr
₹-2.9K Cr
₹-2.2K Cr
₹-2.2K Cr
₹-2.2K Cr
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
₹-439 Cr
₹-439 Cr
₹-463 Cr
₹-463 Cr
₹-493 Cr
₹-493 Cr
₹-515 Cr
₹-515 Cr
₹-501 Cr
₹-501 Cr
₹-480 Cr
₹-480 Cr
₹-500 Cr
₹-500 Cr
₹-365 Cr
₹-365 Cr
₹-338 Cr
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

₹-1.2K Cr
₹-1.2K Cr
₹-2.8K Cr
₹-2.8K Cr
₹-1.3K Cr
₹-1.3K Cr
₹-1.6K Cr
₹-1.6K Cr
₹-1.6K Cr
₹-1.6K Cr
₹-1.8K Cr
₹-1.8K Cr
₹-2.1K Cr
₹-2.1K Cr
₹-2.5K Cr
₹-2.5K Cr
₹-2.0K Cr
₹-2.0K Cr
₹-2.7K Cr
—

Novartis India Ltd · NOVARTIND

₹-455 Cr
₹-455 Cr
₹-492 Cr
₹-492 Cr
₹-543 Cr
₹-543 Cr
₹-532 Cr
₹-532 Cr
₹-482 Cr
₹-482 Cr
₹-578 Cr
₹-578 Cr
₹-591 Cr
₹-591 Cr
₹-632 Cr
₹-632 Cr
₹-613 Cr
₹-613 Cr
₹-665 Cr
—

Pfizer Ltd · PFIZER

₹-1.4K Cr
₹-1.4K Cr
₹-1.5K Cr
₹-1.5K Cr
₹-1.4K Cr
₹-1.4K Cr
₹-1.7K Cr
₹-1.7K Cr
₹-1.8K Cr
₹-1.8K Cr
₹-1.9K Cr
₹-2.0K Cr
₹-2.2K Cr
₹-2.2K Cr
₹-2.7K Cr
₹-2.7K Cr
₹-2.6K Cr
₹-2.6K Cr
₹-3.0K Cr
—

Procter & Gamble Health Ltd · PGHL

₹-456 Cr
₹-218 Cr
₹-218 Cr
₹-316 Cr
₹-316 Cr
₹-398 Cr
₹-398 Cr
₹-423 Cr
₹-423 Cr
₹-415 Cr
—
—
—
—
₹-181 Cr
₹-181 Cr
₹-280 Cr
₹-280 Cr
₹-176 Cr
—
06 · compare level, then change

Return On Capital Employed

Sanofi Consumer Healthcare India Ltd has the highest ROCE among the 8 Pharma - MNC bulk Drugs companies compared here, at 89.9%. Procter & Gamble Health Ltd is next at 83.5%. Procter & Gamble Health Ltd has the highest ROCE change at +14.6 percentage points, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads ROCE at 89.9%, 6.4 percentage points above Procter & Gamble Health Ltd. Procter & Gamble Health Ltd has the strongest latest improvement at +14.6 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderSanofi Consumer Healthcare India Ltd · 89.9%
Gap7.7% versus #2 · Procter & Gamble Health Ltd
PersistenceNot enough history
Coverage8/8 companies · 89 observations

Investor read: Sanofi Consumer Healthcare India Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Sanofi Consumer Healthcare India Ltd SANOFICONR90%
2Procter & Gamble Health Ltd PGHL84%
3Glaxosmithkline Pharmaceuticals Ltd GLAXO61%
4Sanofi India Ltd SANOFI · older report49%
5Abbott India Ltd ABBOTINDIA45%
ROCE changefastest improvers
1Procter & Gamble Health Ltd PGHL+14.6 pp
2Pfizer Ltd PFIZER+4.0 pp
3Abbott India Ltd ABBOTINDIA0.0 pp
4Novartis India Ltd NOVARTIND0.0 pp
5Glaxosmithkline Pharmaceuticals Ltd GLAXO−1.6 pp
Return on capital · company comparison
8/8 level · 6/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

Withheld from this chart: Sanofi Consumer Healthcare India Ltd (SANOFICONR) — its two data sources disagree by up to 132% on reported income across 11 comparable periods, so its derived ratios are withheld; Sanofi India Ltd (SANOFI) — its two data sources disagree by up to 45% on reported income across 6 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyROCEROCE changeReported
Procter & Gamble Health Ltd PGHL74%+14.6 ppMar 2026
Glaxosmithkline Pharmaceuticals Ltd GLAXO49%−1.6 ppMar 2026
Abbott India Ltd ABBOTINDIA36%0.0 ppMar 2026
Astrazeneca Pharma India Ltd ASTRAZEN23%−3.2 ppMar 2026
Pfizer Ltd PFIZER20%+4.0 ppMar 2026
Novartis India Ltd NOVARTIND11%0.0 ppJun 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Abbott India Ltd · ABBOTINDIA

35%
—
34%
—
38%
—
34%
—
39%
50%
36%
47%
40%
52%
36%
47%
41%
52%
36%
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
13%
—
19%
—
25%
—
30%
31%
24%
20%
18%
18%
26%
32%
33%
35%
23%
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

37%
—
25%
—
42%
—
37%
—
43%
42%
41%
44%
50%
63%
51%
61%
58%
71%
49%
—

Novartis India Ltd · NOVARTIND

2.2%
—
3.2%
—
7.5%
—
7.3%
—
6.4%
16%
8.2%
16%
10%
16%
11%
17%
12%
18%
11%
—

Pfizer Ltd · PFIZER

26%
—
24%
—
22%
—
21%
—
18%
21%
16%
24%
17%
23%
16%
27%
19%
29%
20%
—

Procter & Gamble Health Ltd · PGHL

—
30%
—
37%
—
38%
—
37%
44%
37%
36%
33%
36%
38%
59%
56%
58%
52%
74%
—

ROCE change · reported quarter history

Abbott India Ltd · ABBOTINDIA

—
—
—
—
+3.3 pp
—
+0.2 pp
—
+0.5 pp
—
+2.0 pp
—
+1.6 pp
+1.7 pp
+0.1 pp
+0.2 pp
+0.5 pp
−0.3 pp
0.0 pp
—

Astrazeneca Pharma India Ltd · ASTRAZEN

—
—
—
—
—
—
+11.6 pp
—
+11.0 pp
—
−1.0 pp
—
−12.3 pp
−12.4 pp
+2.6 pp
+12.2 pp
+15.0 pp
+16.1 pp
−3.2 pp
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
—
+4.9 pp
—
+12.3 pp
—
+1.0 pp
—
+3.9 pp
—
+6.8 pp
+21.0 pp
+9.3 pp
+17.1 pp
+8.1 pp
+8.4 pp
−1.6 pp
—

Novartis India Ltd · NOVARTIND

—
—
—
—
+5.3 pp
—
+4.1 pp
—
−1.1 pp
—
+0.9 pp
—
+3.9 pp
−0.5 pp
+2.9 pp
+0.8 pp
+1.5 pp
+1.6 pp
0.0 pp
—

Pfizer Ltd · PFIZER

—
—
—
—
−3.7 pp
—
−2.6 pp
—
−4.3 pp
—
−5.4 pp
—
−0.7 pp
+2.3 pp
0.0 pp
+3.1 pp
+2.2 pp
+5.9 pp
+4.0 pp
—

Procter & Gamble Health Ltd · PGHL

—
—
—
—
—
+7.7 pp
—
+0.1 pp
—
−1.1 pp
—
−3.7 pp
−7.3 pp
+0.7 pp
+23.2 pp
+22.9 pp
+22.2 pp
+14.5 pp
+14.6 pp
—
07 · compare level, then change

Valuation Against Growth & Quality

Procter & Gamble Health Ltd has the lowest Guarded PEG among the 8 Pharma - MNC bulk Drugs companies compared here, at 0.5×. Pfizer Ltd is next at 1.19×. Sanofi India Ltd has the lowest P/E at 17.6×, so level and change sit with different companies. 6 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Procter & Gamble Health Ltd has the lowest comparable Guarded PEG at 0.5×, 58% below Pfizer Ltd. Only 6 of 8 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderProcter & Gamble Health Ltd · 0.5×
Gap58% versus #2 · Pfizer Ltd
Persistence0/8 recent comparable periods
Coverage6/8 companies · 59 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
1Procter & Gamble Health Ltd PGHL0.5
2Pfizer Ltd PFIZER1.2
3Novartis India Ltd NOVARTIND2.0
4Abbott India Ltd ABBOTINDIA2.6
5Astrazeneca Pharma India Ltd ASTRAZEN4.0
P/Elowest P/E
1Sanofi India Ltd SANOFI · older report17.6
2Pfizer Ltd PFIZER27.9
3Procter & Gamble Health Ltd PGHL34.1
4Abbott India Ltd ABBOTINDIA38.5
5Novartis India Ltd NOVARTIND41.4
Valuation · company comparison
6/8 level · 8/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyGuarded PEGP/EReported
Glaxosmithkline Pharmaceuticals Ltd GLAXO6.738.1Mar 2026
Astrazeneca Pharma India Ltd ASTRAZEN4.095.3Mar 2026
Abbott India Ltd ABBOTINDIA2.636.4Mar 2026
Novartis India Ltd NOVARTIND2.038.1Jun 2026
Pfizer Ltd PFIZER1.228.2Mar 2026
Procter & Gamble Health Ltd PGHL0.527.5Mar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR—40.0Mar 2026
Sanofi India Ltd SANOFI—39.8Dec 2024
Full 20-quarter history · every available company

Guarded PEG · reported quarter history

Abbott India Ltd · ABBOTINDIA

12.1
4.6
3.3
3.1
3.0
2.2
5.3
1.3
1.7
2.0
2.1
3.8
2.5
2.6
3.0
3.0
2.5
2.3
2.6
—

Astrazeneca Pharma India Ltd · ASTRAZEN

4.0
—
—
—
—
—
—
—
—
—
—
—
—
—
25.3
—
3.1
16.8
4.0
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

—
—
—
—
—
5.8
—
—
0.9
—
1.1
6.0
3.7
1.9
1.6
2.0
—
2.3
6.7
—

Novartis India Ltd · NOVARTIND

—
—
—
—
—
—
—
—
—
—
—
1.2
1.2
—
—
3.3
1.6
—
2.0
—

Pfizer Ltd · PFIZER

4.5
2.3
1.4
—
—
—
—
—
—
—
1.0
—
7.0
2.5
—
—
2.7
2.1
1.2
—

Procter & Gamble Health Ltd · PGHL

—
—
—
—
4.0
2.8
0.6
1.2
1.9
1.8
—
—
—
—
4.2
1.8
0.8
0.9
0.5
—

P/E · reported quarter history

Abbott India Ltd · ABBOTINDIA

63.8
57.7
46.0
48.0
50.3
51.5
50.5
52.4
47.6
44.9
50.3
48.9
50.2
48.4
48.9
52.5
43.5
40.7
36.4
—

Astrazeneca Pharma India Ltd · ASTRAZEN

90.8
109.8
107.3
111.0
108.8
89.5
73.9
70.7
68.3
79.9
83.5
104.3
137.1
123.5
128.4
117.0
104.2
96.0
95.3
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

63.8
63.1
55.0
61.1
58.8
53.9
51.6
40.9
42.9
50.5
51.4
68.4
59.3
48.1
57.1
66.7
47.8
43.8
38.1
—

Novartis India Ltd · NOVARTIND

88.8
85.9
51.3
35.0
18.7
16.5
13.6
19.4
24.9
24.9
26.6
32.0
31.7
26.5
22.5
24.5
21.0
18.2
24.9
38.1

Pfizer Ltd · PFIZER

45.6
39.6
34.3
30.6
35.1
34.8
26.9
28.5
31.7
36.5
37.8
38.0
44.3
36.4
29.8
41.0
33.4
32.7
28.2
—

Procter & Gamble Health Ltd · PGHL

50.6
51.2
46.8
36.3
35.4
32.7
33.4
36.2
37.0
35.5
34.5
39.2
43.7
38.7
34.8
37.8
34.7
30.5
27.5
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
57.3
56.5
51.2
40.0
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
32.5
44.0
44.1
39.8
—
—
—
—
—
—
08 · compare level, then change

Enterprise Value & Book Value

Pfizer Ltd has the lowest EV/EBITDA among the 8 Pharma - MNC bulk Drugs companies compared here, at 17.3×. Procter & Gamble Health Ltd is next at 18.6×. Novartis India Ltd has the lowest P/BV at 4.96×, so level and change sit with different companies. 8 of 8 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Pfizer Ltd leads ev/ebitda at 17.3×; Novartis India Ltd leads p/bv at 4.96×.

LeaderPfizer Ltd · 17.3×
Gap7% versus #2 · Procter & Gamble Health Ltd
Persistence0/8 recent comparable periods
Coverage8/8 companies · 126 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.

EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Pfizer Ltd PFIZER17.3
2Procter & Gamble Health Ltd PGHL18.6
3Novartis India Ltd NOVARTIND21.7
4Abbott India Ltd ABBOTINDIA25.5
5Glaxosmithkline Pharmaceuticals Ltd GLAXO26.1
P/BVlowest P/BV
1Novartis India Ltd NOVARTIND5.0
2Pfizer Ltd PFIZER5.0
3Sanofi India Ltd SANOFI · older report9.1
4Abbott India Ltd ABBOTINDIA12.5
5Glaxosmithkline Pharmaceuticals Ltd GLAXO18.8
Enterprise and book valuation · company comparison
8/8 level · 8/8 change

Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.

All-company data · latest reported quarter

Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyEV/EBITDAP/BVReported
Astrazeneca Pharma India Ltd ASTRAZEN59.724.8Mar 2026
Sanofi Consumer Healthcare India Ltd SANOFICONR28.834.5Mar 2026
Sanofi India Ltd SANOFI28.120.5Dec 2024
Glaxosmithkline Pharmaceuticals Ltd GLAXO26.122.4Mar 2026
Abbott India Ltd ABBOTINDIA25.513.8Mar 2026
Novartis India Ltd NOVARTIND21.74.3Jun 2026
Procter & Gamble Health Ltd PGHL18.613.0Mar 2026
Pfizer Ltd PFIZER17.35.6Mar 2026
Full 20-quarter history · every available company

EV/EBITDA · reported quarter history

Abbott India Ltd · ABBOTINDIA

41.6
37.7
29.7
30.9
33.1
34.2
32.9
34.6
32.1
30.4
34.3
33.4
34.3
33.7
34.1
36.6
30.4
28.6
25.5
—

Astrazeneca Pharma India Ltd · ASTRAZEN

54.3
63.5
60.1
64.4
63.9
55.1
46.6
46.2
45.9
53.6
55.9
69.0
91.8
81.2
84.1
73.9
63.2
60.5
59.7
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

30.7
33.7
29.6
28.5
27.5
25.2
22.2
26.3
27.6
32.8
33.9
44.7
40.0
32.4
38.6
45.3
32.5
30.1
26.1
—

Novartis India Ltd · NOVARTIND

25.2
24.1
15.5
18.2
10.9
9.9
7.7
11.9
13.1
13.6
15.7
17.3
17.4
13.7
11.2
14.2
11.1
9.4
13.2
21.7

Pfizer Ltd · PFIZER

28.2
24.7
21.2
19.7
22.2
21.7
16.2
17.2
18.7
21.9
22.7
23.1
27.6
22.1
17.7
26.3
20.4
20.2
17.3
—

Procter & Gamble Health Ltd · PGHL

31.4
33.2
29.2
24.1
22.6
21.2
21.6
23.7
23.8
22.7
22.0
24.7
27.2
24.8
22.7
25.3
24.2
21.1
18.6
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
34.5
36.1
36.0
39.6
39.4
35.6
28.8
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
—
—
20.2
28.5
30.9
28.1
—
—
—
—
—
—

P/BV · reported quarter history

Abbott India Ltd · ABBOTINDIA

17.3
17.2
14.1
14.8
15.0
16.7
16.6
17.6
15.4
15.6
18.5
18.4
16.8
17.7
18.5
20.1
14.9
15.3
13.8
—

Astrazeneca Pharma India Ltd · ASTRAZEN

16.9
16.4
13.8
15.0
14.3
15.2
15.9
18.1
19.1
21.1
20.3
26.5
25.2
23.4
31.7
31.3
28.6
27.8
24.8
—

Glaxosmithkline Pharmaceuticals Ltd · GLAXO

17.2
23.0
20.2
17.2
16.6
15.4
8.4
13.9
15.1
20.9
21.4
25.3
25.7
23.0
29.2
29.9
23.2
24.4
22.4
—

Novartis India Ltd · NOVARTIND

2.9
2.7
2.1
2.1
2.3
2.3
2.0
2.6
2.3
2.7
3.6
3.5
3.9
3.2
2.7
3.3
2.8
2.5
3.1
4.3

Pfizer Ltd · PFIZER

10.9
9.0
7.8
7.8
6.7
7.0
5.5
6.0
5.5
6.0
5.9
6.5
7.4
5.9
4.9
7.2
5.3
6.0
5.6
—

Procter & Gamble Health Ltd · PGHL

9.9
15.1
11.9
11.5
9.7
10.6
10.6
14.2
13.8
10.9
9.7
10.4
12.2
16.3
14.0
18.3
19.4
15.1
13.0
—

Sanofi Consumer Healthcare India Ltd · SANOFICONR

—
—
—
—
—
—
—
—
—
—
—
—
—
60.9
40.7
42.3
44.3
40.1
34.5
—

Sanofi India Ltd · SANOFI

—
—
—
—
—
—
—
—
14.1
15.7
11.3
14.7
22.7
20.5
—
—
—
—
—
—
09 · let price answer last

Market action

Novartis India Ltd has the strongest one-year price move in Pharma - MNC bulk Drugs at +47.3%. It also leads on Mansfield relative strength against NIFTY at +55.8%. 2 of 8 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.

Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength

Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.

Before the conclusion · check the blind spots

What can make this comparison misleading?

This Pharma - MNC bulk Drugs comparison names 7 specific ways its own evidence can mislead, all listed below. 1 of the 8 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 2 have second-feed figures withheld because the two sources disagree. A high growth rate can still be a low-base artefact.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
  • 2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
  • Thin comparisons: Capital expenditure have fewer than three usable current readings.
10 · the complete set

Which companies are included?

All 8 companies in the canonical Pharma - MNC bulk Drugs membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.

AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.

CompanyMarket valuePricePriced toLatest fundamentalsSource standing
Abbott India Ltd ABBOTINDIAAHEAD₹59.5K Cr₹28,0052026-07-19Mar 2026Cross-checked
Glaxosmithkline Pharmaceuticals Ltd GLAXO₹42.6K Cr₹2,5142026-07-19Mar 2026Cross-checked
Pfizer Ltd PFIZER₹21.2K Cr₹4,6242026-07-19Mar 2026Cross-checked
Astrazeneca Pharma India Ltd ASTRAZEN₹20.0K Cr₹8,0062026-07-19Mar 2026Cross-checked
Procter & Gamble Health Ltd PGHLAHEAD₹11.1K Cr₹6,7142026-07-19Mar 2026Cross-checked
Sanofi Consumer Healthcare India Ltd SANOFICONR19/26 WEEKS₹10.8K Cr₹4,6752026-07-19Mar 2026Second feed withheld
Sanofi India Ltd SANOFI₹7.8K Cr₹3,3892026-07-19Dec 2024Second feed withheld
Novartis India Ltd NOVARTIND₹4.1K Cr₹1,6412026-07-19Jun 2026Cross-checked
How each company's sources stand: 2 of 8 companies have a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Sanofi Consumer Healthcare India Ltd (SANOFICONR) — its two data sources disagree by up to 132% on reported income across 11 comparable periods, so its derived ratios are withheld; Sanofi India Ltd (SANOFI) — its two data sources disagree by up to 45% on reported income across 6 comparable periods, so its derived ratios are withheld.
Evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 8 Pharma - MNC bulk Drugs companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-24.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-24 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing6 cross-checked · 0 unverified · 2 withheld, of 8 graded companies.

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.

Questions investors ask · short, speakable answers

Pharma - MNC bulk Drugs company comparison FAQs

These 18 answers restate the Pharma - MNC bulk Drugs comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.

What is the Nifty Pharma - MNC bulk Drugs index?

The Nifty Pharma - MNC bulk Drugs index tracks India's listed Pharma - MNC bulk Drugs companies as a single basket. This page follows the same 8 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Pharma - MNC bulk Drugs sector rather than to its largest constituent. Figures are as of Jun 2026.

Which are the best Pharma - MNC bulk Drugs stocks in India?

Ranked by this page's four-factor score, Procter & Gamble Health Ltd places first among 8 listed Pharma - MNC bulk Drugs companies, followed by Sanofi Consumer Healthcare India Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Pharma - MNC bulk Drugs stocks are listed in India?

This comparison covers 8 listed Pharma - MNC bulk Drugs companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Pharma - MNC bulk Drugs company is the biggest?

Abbott India Ltd is the largest, with trailing-twelve-month revenue of ₹6,929 crore, ahead of Glaxosmithkline Pharmaceuticals Ltd at ₹3,821 crore. That covers 8 of 8 companies with comparable reporting through Mar 2026.

Which Pharma - MNC bulk Drugs company is growing fastest?

Sanofi Consumer Healthcare India Ltd has the fastest revenue growth at 38.3% year on year, across 7 of 8 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.

Which Pharma - MNC bulk Drugs company has the best profit margins?

Sanofi Consumer Healthcare India Ltd has the highest operating margin at 39%, from 8 of 8 comparable companies. Procter & Gamble Health Ltd shows the biggest recent improvement, at +11 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Pharma - MNC bulk Drugs company makes the most profit?

Abbott India Ltd earns the most, at ₹1,552 crore of trailing-twelve-month net profit, from 8 of 8 comparable companies. Astrazeneca Pharma India Ltd has the fastest profit growth at 63.5%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Pharma - MNC bulk Drugs company earns the highest return on capital?

Sanofi Consumer Healthcare India Ltd leads on return on capital employed at 89.9%, across 8 of 8 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Pharma - MNC bulk Drugs stock is the cheapest?

On guarded PEG — where a LOWER number is cheaper — Procter & Gamble Health Ltd screens cheapest at 0.5×. Only 6 of 8 companies pass the comparability guard, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Which Pharma - MNC bulk Drugs company has the strongest balance sheet?

Novartis India Ltd carries the lowest comparable gross debt at ₹3 crore, from 8 of 8 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.

Which Pharma - MNC bulk Drugs stock has the strongest price momentum?

Novartis India Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Pharma - MNC bulk Drugs company scores highest for research priority?

Procter & Gamble Health Ltd scores 75.1 out of 100 with 89.6% evidence confidence, from 28.7 points on growth and earnings, 20.1 on capital efficiency, 14.6 on valuation and 11.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Pharma - MNC bulk Drugs companies does this comparison cover, and over what period?

It compares 8 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Pharma - MNC bulk Drugs sector?

The 8 Pharma - MNC bulk Drugs companies on this page carry ₹1,77,039 crore of combined market value. Abbott India Ltd is the largest at ₹59,511 crore, about 34% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.

What is the Pharma - MNC bulk Drugs sector's P/E ratio?

The median price-to-earnings ratio across the 8 Pharma - MNC bulk Drugs companies on this page is 41.4×, measured on the 8 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-29.

How is the Pharma - MNC bulk Drugs sector performing?

2 of the 8 covered Pharma - MNC bulk Drugs companies are beating NIFTY 500 on Mansfield relative strength. A 52-week sector-versus-index comparison is not available from the current market series for this sector, so it is not quoted. Readings are as of 2026-07-29.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI